How has the COVID-19 pandemic affected our rheumatology patients using biological/targeted DMARDs?

Conclusions: It was shown that approximately 1/5 of iRMD patients using b/tsDMARDs delayed their treatment due to the fear of COVID-19 in the first three months of the pandemic process. However, with good communication with the patients, b/tsDMARD treatment was restarted and the 12-month drug retention status was quite high.

Source: The Journal of Infection in Developing Countries - July 26, 2023 Category: Infectious Diseases Authors: Semih Gulle, Yesim Erez, Ali Karakas, Tuba Yuce Inel, Sinem Burcu Kocaer, Tuba Demirci Yildirim, Gercek Can, Ismail Sari, Merih Birlik, Fatos Onen Source Type: research